These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28146138)

  • 41. OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.
    LaCroix AZ; Jackson RD; Aragaki A; Kooperberg C; Cauley JA; Chen Z; Leboff MS; Duggan D; Wactawski-Wende J
    Bone; 2013 Oct; 56(2):474-81. PubMed ID: 23735608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
    Arslan MS; Tutal E; Sahin M; Karakose M; Ucan B; Ozturk G; Cakal E; Biyikli Gencturk Z; Ozbek M; Delibasi T
    Endocrine; 2017 Feb; 55(2):410-415. PubMed ID: 27743302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis.
    Pilichou A; Papassotiriou I; Michalakakou K; Fessatou S; Fandridis E; Papachristou G; Terpos E
    Clin Biochem; 2008 Jun; 41(9):746-9. PubMed ID: 18355453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Concentration measurement of the OPG and sRANKL of peripheral blood among normal healthy people].
    Zhu LL; Bao NR; Zhou LW; Guo T; Zeng XF; Zhao JN
    Zhongguo Gu Shang; 2010 Feb; 23(2):87-9. PubMed ID: 20345025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism.
    Pepene CE; Crişan N; Coman I
    Clin Invest Med; 2011 Aug; 34(4):E232. PubMed ID: 21810381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort.
    Sarink D; Yang J; Johnson T; Chang-Claude J; Overvad K; Olsen A; Tjønneland A; Fournier A; Mancini FR; Kvaskoff M; Boeing H; Trichopoulou A; Karakatsani A; Valanou E; Agnoli C; Sacerdote C; Masala G; Mattiello A; Tumino R; Van Gils CH; Skeie G; Gram IT; Weiderpass E; Lujan-Barroso L; Petrova D; Santiuste C; Quirós JR; Barricarte A; Amiano P; Travis RC; Gunter M; Dossus L; Christakoudi S; Kaaks R; Fortner RT
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1746-1754. PubMed ID: 31292137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A study of relationship between dialectical classification according to traditional Chinese medicine of acute coronary syndrome with serum osteoprotegerin and its ligand].
    Luo ZR; Zheng WX; Huang MF; Chen H; Wang ZQ
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Nov; 25(11):673-6. PubMed ID: 24225213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort.
    Tietze H; Pott V; Kanzelmeyer N; Memaran N; Baumann U; Mindermann C; Suhlrie A; Drube J; Melk A; Das AM; Schnabel D; Haffner D; Leifheit-Nestler M
    Osteoporos Int; 2024 Mar; 35(3):533-542. PubMed ID: 37940696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease].
    Xu DR; Su C; Zou WY; Xu HR; Huang S; Li J; Luo SK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):376-80. PubMed ID: 20416172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
    Arslan MS; Sahin M; Karakose M; Tutal E; Topaloglu O; Ucan B; Demirci T; Caliskan M; Ozdemir S; Ozbek M; Cakal E
    Endocr Pract; 2017 Mar; 23(3):266-370. PubMed ID: 27849387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure.
    Loncar G; Bozic B; Cvorovic V; Radojicic Z; Dimkovic S; Markovic N; Prodanovic N; Lepic T; Putnikovic B; Popovic-Brkic V
    Endocrine; 2010 Feb; 37(1):148-56. PubMed ID: 20963564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women.
    Uemura H; Yasui T; Miyatani Y; Yamada M; Hiyoshi M; Arisawa K; Irahara M
    J Endocrinol Invest; 2008 Feb; 31(2):163-8. PubMed ID: 18362509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective effect of zinc supplementation against cadmium-induced oxidative stress and the RANK/RANKL/OPG system imbalance in the bone tissue of rats.
    Brzóska MM; Rogalska J
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):208-20. PubMed ID: 23726800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
    Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
    BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variations in circulating osteoprotegerin and soluble RANKL during diurnal and menstrual cycles in young women.
    Shimizu M; Onoe Y; Mikumo M; Miyabara Y; Kuroda T; Yoshikata R; Ishitani K; Okano H; Ohta H
    Horm Res; 2009; 71(5):285-9. PubMed ID: 19339793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TGF-β1, bone metabolism, osteoprotegerin, and soluble receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Strzelczyk J; Gołąbek K; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2016; 67(5):493-500. PubMed ID: 27828689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation.
    Cao H; Wu Y; Li Q; Wu Y; Zhou Q; Røe OD; Chen Y; Wang R; Wang D
    Int J Cardiol; 2014 Jan; 170(3):298-302. PubMed ID: 24326209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis.
    Hein GE; Meister M; Oelzner P; Franke S
    Rheumatol Int; 2008 Jun; 28(8):765-9. PubMed ID: 18172654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism.
    Nakchbandi IA; Lang R; Kinder B; Insogna KL
    J Clin Endocrinol Metab; 2008 Mar; 93(3):967-73. PubMed ID: 18073309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.